Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund trimmed its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 15.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 340,507 shares of the company's stock after selling 62,437 shares during the quarter. New York State Common Retirement Fund owned about 0.29% of Apellis Pharmaceuticals worth $20,383,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of APLS. IFP Advisors Inc increased its holdings in shares of Apellis Pharmaceuticals by 95.8% during the 3rd quarter. IFP Advisors Inc now owns 3,806 shares of the company's stock worth $145,000 after buying an additional 1,862 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of Apellis Pharmaceuticals by 48.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 6,922 shares of the company's stock worth $263,000 after buying an additional 2,263 shares during the last quarter. Sippican Capital Advisors increased its holdings in shares of Apellis Pharmaceuticals by 77.8% during the 3rd quarter. Sippican Capital Advisors now owns 15,834 shares of the company's stock worth $602,000 after buying an additional 6,930 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Apellis Pharmaceuticals by 0.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 360,287 shares of the company's stock worth $13,705,000 after buying an additional 2,998 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Apellis Pharmaceuticals by 10.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,021 shares of the company's stock worth $533,000 after buying an additional 1,310 shares during the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 18,681 shares of the business's stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $57.18, for a total value of $1,068,179.58. Following the completion of the sale, the director now directly owns 173,998 shares of the company's stock, valued at $9,949,205.64. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director A. Sinclair Dunlop sold 18,681 shares of the business's stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $57.18, for a total value of $1,068,179.58. Following the completion of the sale, the director now directly owns 173,998 shares of the company's stock, valued at $9,949,205.64. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Nur Nicholson sold 835 shares of the business's stock in a transaction on Monday, January 29th. The shares were sold at an average price of $64.14, for a total transaction of $53,556.90. Following the completion of the sale, the insider now directly owns 67,507 shares of the company's stock, valued at $4,329,898.98. The disclosure for this sale can be found here. Insiders sold a total of 381,011 shares of company stock valued at $23,463,657 over the last ninety days. Insiders own 7.50% of the company's stock.

Apellis Pharmaceuticals Stock Up 4.0 %

Shares of Apellis Pharmaceuticals stock traded up $1.93 during trading on Friday, hitting $49.86. 1,215,021 shares of the stock were exchanged, compared to its average volume of 1,146,601. The stock has a market cap of $6.01 billion, a price-to-earnings ratio of -11.13 and a beta of 0.88. The firm's 50-day moving average price is $57.84 and its 200 day moving average price is $57.53. Apellis Pharmaceuticals, Inc. has a 12-month low of $19.83 and a 12-month high of $94.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.73). The business had revenue of $146.38 million during the quarter, compared to analysts' expectations of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company's revenue for the quarter was up 545.9% on a year-over-year basis. During the same period in the previous year, the company earned ($1.50) EPS. As a group, analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on APLS shares. Mizuho restated a "neutral" rating and set a $60.00 price target on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th. Jefferies Financial Group upgraded shares of Apellis Pharmaceuticals from a "hold" rating to a "buy" rating and lifted their target price for the company from $68.00 to $80.00 in a report on Monday, February 5th. Wedbush dropped their target price on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a "neutral" rating for the company in a report on Wednesday, April 17th. Robert W. Baird reiterated an "outperform" rating and issued a $81.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, February 6th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an "overweight" rating in a report on Wednesday, March 6th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $77.93.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).